Hedberg et al reported specifically on patients with PI3K-altered HNSCC treated primarily with surgery and found a significant 5-year DSS and 5-year OS advantage for patients taking NSAIDs.12 Although we were unable to test for PI3K, our results suggest an OS advantage but not a DSS advantage. This evidence concerns the gene PIK3CA and head and neck squamous cell carcinoma.